Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. (Q37708869)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alessio Bruni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

V Scotti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

L Livi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C De Luca Cardillo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Galardi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Cipressi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

G Biti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

published in

Journal of Chemotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

58-62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Breast cancer: bisphosphonate therapy for metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Efficacy of ibandronate in metastatic bone disease: review of clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Ibandronate: efficacy in the treatment of metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Ibandronate: its role in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Managing metastatic bone pain: the role of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Renal Failure with the Use of Zoledronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Renal safety of ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2010.22.1.58

21 January 2018

Identifiers

DOI

10.1179/JOC.2010.22.1.58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20227995%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference